A Phase 4 interventional study of Vancomycin and Linezolid in Pneumonia, Ventilator-Associated, sponsored by Pfizer. Completed at 37 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2010-06-09.
Sponsored by Pfizer · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 62 studies in Pneumonia, Ventilator-Associated with a site in United States — 4 open to participants now, 5 under way, none of them phase 3. Pneumonia, Ventilator-Associated · United States.
Among the 62 studies in Pneumonia, Ventilator-Associated with a site in United States, this one is the 25th largest by enrollment of the 49 interventional ones that give a count, is one of 3 that started in 2002, is one of 7 in phase 4, and was the 13th registered.
420 studies on the registry are indexed under Pneumonia, Ventilator-Associated; 83 are open to participants now.
Browse Pneumonia, Ventilator-Associated studies →4 of the 62 studies in Pneumonia, Ventilator-Associated with a site in United States are open now. Recruiting first, the newest first:
Northwell Health · Sites in United States
Ages 0–18
University of Florida · Sites in United States
Ages 1 hrs–3 days
William Janssen, MD · Sites in United States
Ages 18–99
Johns Hopkins University · Sites in United States
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 47 Pneumonia, Ventilator-Associated studies recruiting now, 36 (77%) set no upper age limit and 6 (13%) stop at 75 or younger; 6 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
62 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 12 · Phase 3 10 · Phase 4 7
First in 2001; this study’s year is marked. 3 started in 2002.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 149 is above the median of 115 across 276 interventional studies indexed under Pneumonia, Ventilator-Associated.
Median enrollment 149 across the 49 interventional studies, 70 across the 13 observational. Of the 54 that completed or were terminated, 26 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 62 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Pfizer has 9 studies filed under Pneumonia, Ventilator-Associated — fewer than ten, so there is no comparison to draw.
2 of the studies in Pneumonia, Ventilator-Associated with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04987840Johns Hopkins UniversityA Multi-Center Diagnostic Stewardship Program to Improve Respiratory Culture Utilization in Critically Ill Children | 2026-12-01 |
| NCT05767671William Janssen, MDMacrophage Programing in Acute Lung Injury: MiniBAL | 2027-09-18 |
Add all 2 to your calendar (.ics) → With an account.
Among the 62 studies in Pneumonia, Ventilator-Associated with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Ventilator-associated pneumonia (VAP) is a commonplace complication of intensive care patients ventilated for longer than 48 hours. Methicillin-resistant Staphylococcus aureus (MRSA) is the cause of late onset VAP in up to about 30% of cases in US hospitals. Ineffective treatment of MRSA VAP clearly leads to prolonged mechanical ventilation and is probably associated with higher mortality. The purpose of this protocol is to directly compare linezolid and vancomycin specifically for MRSA VAP.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Vancomycin
Drug: Linezolid
1 gram IV every 12 hours for 7 to 14 days
600 mg every 12 hours (intravenously \[IV\] for a minimum of the first 4 days followed by a switch to oral if tolerated by patient) for a total duration of 7 to 14 days
To assess early microbiologic response in patients with VAP due to MRSA based on semi-quantitative culture of bronchoscopic bronchoalveolar lavage (BAL) in patients treated with linezolid vs vancomycin.
Time frame: 72-96 hours
To compare duration of mechanical ventilation
Time frame: 0000
To compare post treatment tracheal colonization
Time frame: FU: 14 days after EOT +/- 2 days
To identify clinical correlates of infection based on microbiologic sampling as determined by original and modified CPIS (Clinical Pulmonary Infection Score)
Time frame: EOT: Day 14; FU: 14 days after EOT +/- 2 days
To compare the microbiological cure based on BAL specimens with the traditional criteria for microbiologic cure
Time frame: 72-96 hours
To compare mortality at End Of Treatment (EOT) and Follow up (FU); To compare clinical outcome at EOT and FU
Time frame: EOT: Day 14; FU: 14 days after EOT +/- 2 days
The record gives a start of Nov 2002 and a completion of Jan 2005. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Vancomycin · Linezolid
Pneumonia, Ventilator-Associated →